Compare · NVS vs SNPX
NVS vs SNPX
Side-by-side comparison of Novartis AG (NVS) and Synaptogenix Inc. (SNPX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVS and SNPX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $274.13B, about 5447.0x SNPX ($50.3M).
- Over the past year, NVS is up 22.8% and SNPX is up 851.5% - SNPX leads by 828.7 points.
- NVS has more recent analyst coverage (25 ratings vs 0 for SNPX).
- Company
- Novartis AG
- Synaptogenix Inc.
- Price
- $143.69+0.15%
- $24.74+1.83%
- Market cap
- $274.13B
- $50.3M
- 1M return
- -0.64%
- -10.98%
- 1Y return
- +22.84%
- +851.54%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 0
- 0
- Recent ratings
- 25
- 0
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Synaptogenix Inc.
Synaptogenix, Inc. operates as a biopharmaceutical company. It focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and niemann-pick type C disease. It has licensing agreements with Stanford University; Icahn School of Medicine; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is based in New York, New York.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
- SEC Form 20-F filed by Novartis AG
- Citigroup initiated coverage on Novartis AG
Latest SNPX
- SEC Form DEF 14A filed by Synaptogenix Inc.
- Director Singer William S. was granted 15,410 shares and covered exercise/tax liability with 6,164 shares, increasing direct ownership by 700% to 10,566 units (SEC Form 4)
- Chief Financial Officer Weinstein Robert was granted 15,410 shares and covered exercise/tax liability with 6,164 shares, increasing direct ownership by 696% to 10,574 units (SEC Form 4)
- Executive Chairman Silverman Joshua was granted 41,919 shares and covered exercise/tax liability with 16,768 shares, increasing direct ownership by 1,644% to 26,681 units (SEC Form 4)
- Director Schechter Jonathan was granted 21,575 shares and covered exercise/tax liability with 8,630 shares, increasing direct ownership by 1,188% to 14,035 units (SEC Form 4)
- Director Bernstein Bruce covered exercise/tax liability with 9,863 shares and was granted 24,657 shares, increasing direct ownership by 1,341% to 15,897 units (SEC Form 4)
- Chief Medical Officer Tuchman Alan J was granted 4,315 shares and covered exercise/tax liability with 1,726 shares, increasing direct ownership by 196% to 3,909 units (SEC Form 4)
- TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today
- SEC Form PRE 14A filed by Synaptogenix Inc.
- Synaptogenix Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits